Abstract B29: The role of MYD88-dependent signaling in the anti-tumor efficacy of the EGFR inhibitor erlotinib in head and neck cancer cells

Abstract

Peer reviewed

Andrean L Simons, Adam T Koch, Laurie Love-Homan and Aditya Stanam

Clinical cancer research, Vol.21(4 Supplement), pp.B29-B29

02/15/2015

DOI: 10.1158/1557-3265.PMS14-B29

View Online

Title: Subtitle: Abstract B29: The role of MYD88-dependent signaling in the anti-tumor efficacy of the EGFR inhibitor erlotinib in head and neck cancer cells
Creators: Andrean L Simons - University of Iowa
Adam T Koch - University of Iowa
Laurie Love-Homan
Aditya Stanam - University of Iowa
Resource Type: Abstract
Publication Details: Clinical cancer research, Vol.21(4 Supplement), pp.B29-B29
DOI: 10.1158/1557-3265.PMS14-B29
ISSN: 1078-0432
eISSN: 1557-3265
Language: English
Date published: 02/15/2015
Academic Unit: Oral Pathology, Radiology and Medicine; Pathology; Pharmaceutical Sciences and Experimental Therapeutics; Radiation Oncology
Record Identifier: 9984201527002771

5 Record Views